Clinical Trials Sponsored by Joliet Center for Clinical Research

Total 7038 results

Swiss Group for Clinical Cancer Research

Completed

Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Esophageal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung

Malignant Mesothelioma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer

Gastric Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Leukemia

Switzerland
Center for Clinical Pharmacology Research Bdbeq...

Completed

Fed Bioequivalence Study of CBZ Formulations

Bio-equivalence Study | Fed Conditions

Uruguay
Clinical Research Center for Solid Tumor, Korea

Completed

A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer

Small Cell Lung Cancer

Korea, Republic of
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Leukemia | Chronic Lymphocytic Leukemia | Relapsed/Refractory Chronic Lymphocytic Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
Swiss Group for Clinical Cancer Research

Completed

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Lung Cancer

Germany, Serbia, Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Small Cell Lung Cancer | Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (OptiPOM)

Refractory Multiple Myeloma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Biological Therapy in Treating Patients With Bladder Cancer

Bladder Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

France, Switzerland, Germany, Finland
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Liver Cancer

Switzerland, Austria, Hungary
Swiss Group for Clinical Cancer Research

Completed

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

Switzerland, Germany
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

Switzerland, Netherlands
Swiss Group for Clinical Cancer Research

Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lymphoma

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Withdrawn

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma

France, Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Drugs to Reduce the Side Effects of Chemotherapy

Unspecified Adult Solid Tumor, Protocol Specific | Nausea and Vomiting

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery

Esophageal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer

Esophageal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Pain | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Chemotherapy in Treating Patients With Advanced Sarcoma

Sarcoma | Ovarian Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer

Gastric Cancer

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Bladder Cancer

Switzerland

Clinical Trials Sponsored by Joliet Center for Clinical Research

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations